Physician profile
James B Friedlander
NPI 1265932131
$2,923.59
in general payments reported to CMS, 2019-2025
28 companies · $18.23 in 2025
The $18.23 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $532 · 2022: $1,155 · 2023: $911 · 2024: $308 · 2025: $18.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,217 · Long Term Medical Supply Or Device Loan: $19.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,217.01 |
| Long Term Medical Supply Or Device Loan | $19.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $394.97 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $281.24 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $261.30 | 2021-2022 | |
| Abbvie INC. | $259.80 | 2021-2025 | |
| Novo Nordisk INC | $226.05 | 2022-2024 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $219.48 | 2021-2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $181.01 | 2023-2024 | Trulance, Xifaxan |
| Pfizer INC. | $131.50 | 2021-2024 | |
| Amarin Pharma, INC. | $130.95 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $118.92 | 2021-2023 | Farxiga |
| Gilead Sciences, INC. | $100.00 | 2021 | |
| Amgen INC. | $88.92 | 2022-2024 | Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $74.77 | 2022-2023 | |
| Abbott Laboratories | $72.92 | 2021-2024 | Freestyle Insulinx |
| Lilly USA, LLC | $61.26 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $45.60 | 2021-2023 | Pneumovax 23, Vaxneuvance, Gardasil 9 |
| Eisai INC. | $43.47 | 2021 | |
| Horizon Therapeutics Plc | $42.62 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $33.94 | 2023 | Eliquis |
| Dexcom, INC. | $33.71 | 2023-2024 | Dexcom G6 Transmitter |
| Renalytix Ai, INC. | $20.09 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Esperion Therapeutics, INC. | $15.43 | 2023 | Nexletol |
| Mannkind Corporation | $15.31 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $15.00 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.90 | 2023 | Quviviq |
| Nestle Healthcare Nutrition INC. | $14.50 | 2022 | |
| Dynavax Technologies Corporation | $14.26 | 2022 | |
| Shield Therapeutics INC | $11.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Friedlander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.